EUCTR2008-005967-33-IT进行中（未招募）不适用
randomized phase II trial of two different sequences in first line chemotherapy of advanced non small cell lung cancer - ND
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI0 个研究点开始时间: 2009年3月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •cito-histologically confirmed NSCLC- MALE OR FEMALE <75 YEARS- informed written consensus- adequate hematochemic function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •concurrent chronic systemic immune therapy- radically resected disease- any investigational agent 4 weeks prior to entry-3-4 degree alergic reaction to any of the components of the treatment
研究者
相似试验
进行中（未招募）
不适用
Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.on Small Cell Lung cancerMedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-001044-72-ITAVENTIS PHARMA S.P.A.84
进行中（未招募）
1 期
Comparison of two concomitant administration of radiotherapy with cisplatin in standard infusion (1 time every 21 days) or fractional infusion ( 4 times every 21 days)MedDRA version: 18.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001928-29-FRGORTEC92
进行中（未招募）
1 期
A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancerEUCTR2019-004196-39-FRICANCER340
进行中（未招募）
不适用
Abraxane and Gemcitabine versus Gemcitabine alone in locally advanced unresectable pancreatic cancer.124 locally advanced unresectable pancreatic cancer patients will be randomized in a 1:1 ratio to receive abraxane/gemcitabine (arm A) or gemcitabine alone (arm B), as first-line chemotherapyEUCTR2013-002973-23-ITFondazione GISCAD
进行中（未招募）
不适用
Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck. - ICRATPatients with histologically proven unresectable squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx (stage IVa & IVb).EUCTR2010-019347-18-DECharité - Universitätsmedizin Berlin